Fuji Pharma (4554) · InitiativeSoftened
Expansion of Injection Manufacturing Equipment and Syringe Line at Toyama Plant
First written in FY2021. 1 of 2 entries say "Softened", first in FY2022. Latest entry: FY2022.
2entries
2years
0from disclosures
How it moved
Same theme, other companies
Strengthening Pharmaceutical Production Sites and Meeting Quality StandardsA theme 7 companies write about · 0 as a headwind · 10 as a tailwind
Fuji Pharma moved to the "Worse" side of this theme in 2022.
0 other companies' latest entry also says "Softened".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
- FY2022SoftenedAnnual report
「Toyama Plant (Toyama Prefecture) Injectable manufacturing facilities 3,950 1,296 Internal funds, etc. March 2021 October 2023」
The scheduled completion date for the injectable manufacturing facilities changed from May 2023 to October 2023, and the amount already paid is ¥1,296 million. - FY2021First statedAnnual report
「Toyama Plant Injectable drug production equipment ¥3,950 million ¥512 million Internal funds, etc. March 2021 May 2023」
For the first time, provides specific details of a plan to install injectable manufacturing facilities at the Toyama Plant, with a total investment of ¥3,950 million, ¥512 million already paid, and completion scheduled for May 2023. The equipment details also mention construction to expand the syringe line in the fifth formulation building.